All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ELE-Psilo+
Therapeutic Area: Psychiatry/Psychology Product Name: ELE-Psilo+
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Eleusis
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition December 14, 2020
Details:
ELE-Ket+ and ELE-Psilo+ are expected to enter Phase II clinical trials for the adjunctive treatment of major depressive disorder at the end of 2021. Under the terms of the agreement, Eleusis will acquire Kalypso and its intellectual property in an all-stock transaction.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Nalmefene
Therapeutic Area: Psychiatry/Psychology Product Name: OPNT003
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: BARDA
Deal Size: $8.1 million Upfront Cash: Undisclosed
Deal Type: Funding December 14, 2020
Details:
An earlier award of $4.6 million from BARDA, combined with a $7.4 million grant Opiant received from the NIDA, also supports the clinical development and U.S. regulatory submission of OPNT003. The grant increases total potential value of the BARDA contract to $8.1 million.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): STP1
Therapeutic Area: Psychiatry/Psychology Product Name: STP1
Highest Development Status: Phase I Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 11, 2020
Details:
STP1 is a novel combination of compounds: a pan-PDE inhibitor with anti-inflammatory properties and a modulator of NKCC1, specifically targeting the biological dysregulations linked to ASD-Phen1.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Psilocybine
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: University of Wisconsin
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 11, 2020
Details:
Under its sponsored research partnership with University of Wisconsin-Madison, the Company is developing its tannin-chitosan composite of orally dissolvable thin films which offers a unique delivery platform for therapeutic doses (1-20mg) of psilocybin into the oral cavity.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): D-Amphetamine Sulfate
Therapeutic Area: Psychiatry/Psychology Product Name: ADAIR
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2020
Details:
Results demonstrated that ADAIR had slower absorption and lower early exposure, and was less desirable to recreational drug abusers on key measures of abuse liability compared to commercially available dextroamphetamine.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Nalmefene
Therapeutic Area: Psychiatry/Psychology Product Name: OPNT003
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Opiant Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership October 29, 2020
Details:
Agreement combines Opiant’s opioid antagonist OPNT003 nasal nalmefene, with Aptar's FDA-approved Unit Dose System delivery device. OPNT003 is a nasal nalmefene for use in conjunction with Aptar’s Unit Dose System (UDS) for the treatment of opioid overdose.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): D-Amphetamine Sulfate
Therapeutic Area: Psychiatry/Psychology Product Name: ADAIR
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering October 23, 2020
Details:
The company's clinical-stage product currently under development is Abuse-Deterrent Amphetamine Immediate-Release, or ADAIR. ADAIR has completed a Phase 1 pivotal bioequivalence study and a Phase 1 food effect study.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Psilocybine
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Mind Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 24, 2020
Details:
As part of this exclusive license agreement MindMed will retain an exclusive license to all IP and any patents generated from data or findings in the study and related work on psilocybin, such as pharmacokinetic data and information on the metabolism.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ASP8062
Therapeutic Area: Psychiatry/Psychology Product Name: ASP8062
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding September 22, 2020
Details:
Should the phase 1 studies demonstrate appropriate safety measures, a second phase of the grant may be awarded to help fund a randomized double-blind phase 2 study to assess the safety and efficacy of ASP8062 on the reduction of opioid use in OUD patients.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Psilocybine
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: University of Wisconsin-Madison
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2020
Details:
Revive Therapeutics is developing its tannin-chitosan composite of orally dissolvable thin films which offers a unique delivery platform for therapeutic doses (1-20mg) of psilocybin into the oral cavity.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
